CraniUS Therapeutics Closes $20 Million Series B Round to Advance NeuroPASS™ Platform Towards Future Commercialization

CraniUS Therapeutics完成2000万美元B轮融资，推动NeuroPASS™平台走向未来商业化

Enabling Direct Therapeutic Access Beyond the Blood-Brain Barrier

超越血脑屏障的直接治疗通道的启用

BALTIMORE, January 28, 2026-- CraniUS Therapeutics LLC, a privately held neurotechnology company, today announced it has raised $20 million in Series B financing to accelerate development of NeuroPASS™, a fully implantable, skull-embedded platform designed to bypass the blood-brain barrier (BBB) and enable targeted drug delivery and monitoring in the brain..

巴尔的摩，2026年1月28日——CraniUS Therapeutics LLC，一家私有的神经技术公司，今天宣布已完成2000万美元的B轮融资，以加速NeuroPASS™的开发。NeuroPASS™是一个完全可植入、嵌入颅骨的平台，旨在绕过血脑屏障（BBB），实现大脑内的靶向药物递送和监测。

NeuroPASS™ is being developed as a multi-product platform, with an initial roadmap of three complementary products intended to progressively expand therapeutic capability. Together, these devices are intended to evolve cranial implants from passive reconstructive hardware into an active therapeutic interface capable of supporting long-term outpatient care..

NeuroPASS™ 正在被开发为一个多产品平台，初步规划了三个互补的产品，旨在逐步扩展治疗能力。这些设备共同将颅骨植入物从被动的重建硬件发展为主动的治疗接口，能够支持长期的门诊护理。

CraniUS Therapeutics was founded by Dr. Chad Gordon, a Johns Hopkins neuroplastic surgeon and pioneer of the new surgical field known as Neuroplastic Surgery, who has spent more than 15 years studying and investigating the temporal cranial space as an optimal site for therapeutic delivery. The company was born from a persistent clinical challenge Dr.

CraniUS Therapeutics 由约翰霍普金斯大学的神经整形外科医生、新外科领域“神经整形手术”的先驱者查德·戈登博士创立，他花费了超过15年的时间研究和探索颞颅空间作为治疗传递的最佳位置。公司源于一个长期存在的临床挑战。

Gordon encountered in practice: patients with devastating neurological diseases often succumbed not because surgery could not help, but because life-saving medicinal therapies could not reach the brain due to the BBB..

戈登在实践中遇到的情况是：患有严重神经疾病的人通常并不是因为手术无法帮助他们而屈服，而是因为挽救生命的药物疗法由于血脑屏障而无法到达大脑。

'This is not an incremental advance—it represents a fundamentally new approach to treating neurological disease and brain cancer,' said Dr. Gordon, Founder and Executive Chair of CraniUS Therapeutics. 'We set out to build a platform that could help address a therapeutic barrier that has limited care for decades.'.

“这不是一个渐进的进展——它代表了一种治疗神经系统疾病和脑癌的全新方法，”CraniUS Therapeutics创始人兼执行主席戈登博士说道，“我们着手构建一个平台，以帮助解决几十年来一直限制治疗的障碍。”

The Series B financing follows CraniUS's $20 million Series A round in 2022. The Series B includes $19 million from private investors and $1 million in non-dilutive funding from the State of Maryland, bringing total capital raised to approximately $40 million. The new capital is expected to support operations into 2027 and will support regulatory submissions, manufacturing scale-up and product testing towards future commercialization..

CraniUS公司在2022年完成了2000万美元的A轮融资，此次B轮融资紧随其后。B轮融资包括来自私人投资者的1900万美元和马里兰州提供的100万美元非稀释性资金，使得总融资额达到约4000万美元。新资金预计将支持公司运营至2027年，并将用于监管申报、生产规模扩大以及未来商业化的产品测试。

CraniUS holds 15 issued domestic patents supporting its platform and long-term product roadmap, as well as numerous international patents.

CraniUS 拥有 15 项已授权的国内专利，支持其平台和长期产品路线图，同时还拥有众多国际专利。

'Having led large academic health systems and worked at the intersection of care delivery and innovation, we've put robots in operating rooms and AI in radiology suites, but the blood-brain barrier has stubbornly ignored a century of pharmaceutical and medical device innovation, said Dr. Stephen Klasko, a member of the CraniUS board of directors.' 'NeuroPASS represents exactly the kind of 'why not?' thinking that transforms medicine, not incremental improvement, but a fundamental reimagining of how we access the brain.'.

“在领导大型学术健康系统并在医疗服务和创新的交汇处工作时，我们已经在手术室中引入了机器人，在放射科套件中应用了人工智能，但血脑屏障却顽固地忽视了一个世纪以来的医药和医疗设备创新，”CraniUS董事会成员Stephen Klasko博士说道。“NeuroPASS正是那种‘为什么不？’的思维方式的体现，它将改变医学，不是渐进式的改进，而是对我们如何接触大脑的一种根本性重新构想。”

About CraniUS Therapeutics CraniUS Therapeutics is a neurotechnology company developing the first fully implantable platform to bypass the blood-brain barrier for long-term, programmable drug delivery. Its flagship device, NeuroPASS™, is designed to transform the treatment landscape for debilitating neurological conditions across multiple disease types by leveraging the temporal skull space.

关于CraniUS治疗公司 CraniUS治疗公司是一家神经技术公司，正在开发首个完全可植入的平台，以绕过血脑屏障实现长期、可编程的药物输送。其旗舰设备NeuroPASS™旨在通过利用颞骨颅腔空间，改变多种疾病类型中令人衰弱的神经系统疾病的治疗格局。

CraniUS Therapeutics is headquartered in Baltimore, Maryland, and collaborates globally with industry leading experts in neurosurgery, drug delivery, implant design, device engineering, and manufacturing..

CraniUS Therapeutics总部位于马里兰州巴尔的摩，并与全球神经外科、药物输送、植入物设计、设备工程和制造领域的行业领先专家合作。

Important Regulatory Notice

重要监管通知

NeuroPASS™ is an investigational device and has not been approved or cleared by the U.S. Food and Drug Administration for clinical use. All described uses are under development and subject to regulatory review.

NeuroPASS™ 是一种研究性设备，尚未获得美国食品药品监督管理局（FDA）的临床使用批准或认证。所有描述的用途均处于开发阶段，并需接受监管审查。

Contact:

联系：

Media Contact:

媒体联系人：

Elizabeth Dale

伊丽莎白·戴尔

Executive Advisor, Strategic Partnerships & External Relations

执行顾问，战略合作伙伴关系与外部关系

edale@craniusmed.com

edale@craniusmed.com

www.craniusmed.com

www.craniusmed.com